Enzo Biochem (ENZ)
(Delayed Data from NYSE)
$1.11 USD
-0.02 (-1.77%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $1.12 +0.01 (0.90%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.11 USD
-0.02 (-1.77%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $1.12 +0.01 (0.90%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
ARIAD Pharma Stock Gains on Acquisition Deal with Takeda
by Zacks Equity Research
ARIAD Pharmaceuticals, Inc.'s (ARIA) shares surged 72.8% after the company announced a definitive agreement to be acquired by Japan-based Takeda Pharmaceutical Company Limited (TKPYY) for approximately $5.2 billion.
Halozyme Therapeutics (HALO) in Focus: Stock Up 6.4%
by Zacks Equity Research
Halozyme Therapeutics, Inc. (HALO) saw its shares rise above 6% in the last trading session.
5 Small Cap ETFs and Stocks to Play January & Trump Effect
by Sweta Killa
Small caps would enjoy the dual tailwinds of the January Effect and Trump policies.
New Strong Buy Stocks for December 29th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
5 Reasonable Breakout Stocks for Exceptional Returns
by Swarup Gupta
If properly implemented, such a strategy could deliver impressive returns.
5 Top Performing Biotechnology Stocks of November
by Zacks Equity Research
November was a great month for pharma/biotech stocks after a rather difficult year when the industry struggled with media and political focus on high drug prices.
The Zacks Analyst Blog Highlights: Enzo Biochem, Exelixis, Genmab A/S, Heska and Incyte
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Enzo Biochem, Exelixis, Genmab A/S, Heska and Incyte
Zacks.com featured highlights: include Cambrex, Enzo Biochem, Alliqua BioMedical, CubeSmart and Snap-on
by Zacks Equity Research
Zacks.com featured highlights: include Cambrex, Enzo Biochem, Alliqua BioMedical, CubeSmart and Snap-on
New Strong Buy Stocks for July 11th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday